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Abstract: Hypertension is the strongest independent modifiable risk factor for cardiovascular dis-
ease. We aimed to investigate the association of magnesium intake with incident hypertension in a
Mediterranean population, and the potential modification of this association by body mass index
(BMI). We assessed 14,057 participants of the SUN (Seguimiento Universidad de Navarra) prospective
cohort (67.0% women) initially free of hypertension. At baseline, a validated 136-item food frequency
questionnaire was administered. We used Cox models adjusted for multiple socio-demographic,
anthropometric, and lifestyle factors, and prevalent conditions present at baseline. Among a mean
9.6 years of follow-up we observed 1406 incident cases of medically diagnosed hypertension. An in-
verse association in multivariable-adjusted models was observed for progressively higher magnesium
intake up to 500 mg/d vs. intake < 200 mg/d, which was greater among those with a BMI > 27 kg/m2.
Lean participants with magnesium intake < 200 mg/d vs. >200 mg/d also had a higher risk of
incident hypertension. Adherence to the Mediterranean diet did not modify these associations. In
conclusion, dietary magnesium intake < 200 mg/d was independently associated with a higher risk
of developing hypertension in a Mediterranean cohort, stronger for overweight/obese participants.
Our results emphasize the importance of encouraging the consumption of magnesium-rich foods
(vegetables, nuts, whole cereals, legumes) in order to prevent hypertension.
Keywords: magnesium; hypertension; obesity; overweight; diet; cohort studies
1. Introduction
Hypertension is the strongest independent and modifiable risk factor for heart failure,
stroke, myocardial infarction, chronic kidney disease, and cognitive decline [1]. In 2015,
hypertension was associated with 4.9, 2.0, and 1.5 million deaths due to ischemic heart
disease and hemorrhagic and ischemic stroke, respectively [2]. Currently, 1.13 billion adults
have hypertension worldwide according to the World Health Organization (WHO) [3]
and its prevalence is still increasing [4]. Therefore, public health preventive strategies are
urgently needed to fight the hypertension pandemic.
Magnesium is involved in fundamental cellular processes comprising adenosine
triphophosphate-dependent biochemical reactions, deoxyribonucleic acid synthesis, ri-
bonucleic acid expression, muscular and neural cell signaling, glucose metabolism, and
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blood pressure control [5,6]. Magnesium is involved in the regulation of blood pressure by
diverse mechanisms including vascular tone and reactivity modulation acting as a calcium
antagonist [7,8], the renin–angiotensin–aldosterone system [9], endothelial function [10–12],
vascular remodeling and stiffness [13], and catecholamine release [14].
Magnesium is abundant in nuts, in green leafy vegetables, in legumes, and in whole
cereals, whereas it is practically absent in processed foods [15]. Dietary magnesium intake
is insufficient in a large proportion of European and US populations where Western dietary
patterns full of processed foods are usual [16–19]. The Dietary Guidelines for Americans
recommend a daily intake of 420 mg of magnesium for men and 320 mg for women [20],
but estimates indicate that over 60% of Americans are below this recommendation [18].
Magnesium has to be consumed regularly to prevent deficiency, which is associated
with oxidative stress and low-grade inflammation [12,21,22], and with an increased risk of
a number of clinical conditions including hypertension and stroke [5,7,23]. Previous studies
have shown inverse associations of magnesium intake in the diet with the risk of hyperten-
sion [24–31], with fewer reporting negative or inconclusive results [32–34]. A systematic
review and meta-analysis of cohort studies reported a 5% lower risk of incident hyperten-
sion for each 100 mg/day higher magnesium intake [35]. Two meta-analyses of randomized
controlled trials (RCTs) found that participants receiving magnesium supplements had
a significant reduction in blood pressure vs. controls [36,37]. Former meta-analyses sug-
gested benefits with less prominent effects, possibly due to heterogeneity of included
studies [38,39].
Previous large long-term prospective studies evaluating the relationship of dietary
magnesium with hypertension have been conducted mainly in the United States [35], but
none in Mediterranean populations. Because overweight and obesity are major risk factors
for the development of hypertension [40], we aimed to prospectively assess the association
of magnesium intake with the risk of incident hypertension in relation to the presence
of overweight and obesity in the Mediterranean population of the SUN (“Seguimiento
Universidad de Navarra”) longitudinal project.
2. Methods
2.1. Study Design and Population
The SUN Project is a prospective, longitudinal, multipurpose, and permanently open
cohort study of university graduates started in 1999, updated every 2 years with informa-
tion on lifestyle, diet, risk factors, and medical conditions during follow-up, as previously
described in detail [41,42]. For the present analyses, we considered the last available
database as of 1 December, 2016, corresponding to 22,560 enrolled participants. We ex-
cluded (a) 4404 who had prevalent hypertension at baseline; (b) 260 who answered the
baseline questionnaire after 1 March, 2014, not having spent sufficient time in the study as
to be able to fill and return the first follow-up questionnaire (<2 years plus 9 months consid-
ering the time interval to return the questionnaires); (c) 1721 participants who reported total
energy intake outside of predefined limits (<500 or >3500 kcal/day for women and <800
or >4000 kcal/day for men) [43]; (d) 753 with other chronic diseases at baseline (diabetes,
cardiovascular disease, or cancer); and (e) 1365 participants who were lost to follow up. The
final analytic population included 14,057 participants (Figure S1 Supplementary Materials).
The overall retention rate was 91.2% (91.2% of participants recruited at least 2 years and
9 months ago returned ≥1 of the follow-up questionnaires).
2.2. Ethics
Participants received written information on their specific data to be requested by
future questionnaires, the future feedback from the research team, and the protection to
safeguard their privacy. We also informed all potential candidates of their right to refuse
to participate in the SUN study or to withdraw their consent to participate at any time
without retaliation, according to the principles of the Declaration of Helsinki. The voluntary
completion of the baseline questionnaire was considered to imply informed consent. The
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Research Ethics Committee of the University of Navarra approved this method to request
the informed consent of participants (Project identification code 2001_30).
2.3. Dietary and Exposure Assessment
The details of the dietary assessment with a validated semi-quantitative 136-item
food frequency questionnaire (FFQ) in the SUN Project at baseline has been previously
described [44]. The content of nutrients in the FFQ was calculated as previously de-
scribed [44–46] by means of the latest available Spanish food composition tables [47,48].
The FFQ also contained additional questions about vitamin and mineral supplements, such
as magnesium [41]. The validity [44,45] and reproducibility [46] of the FFQ has been previ-
ously reported. The last validation study showed a high intra-class correlation coefficient
(ICC) between the questionnaire and the reference method (four 3-day dietary records) for
dietary components (ICC = 0.66 and ICC = 0.75 after energy adjustment; both p < 0.001).
The reproducibility study showed similarly high ICCs, with corresponding values of 0.86
and 0.88, respectively [45]. Dietary magnesium was calculated from magnesium-rich foods
assessed with a 136-item FFQ. Total magnesium intake was computed as the sum of dietary
magnesium and magnesium intake derived from supplements [44]. Nutrient scores were
calculated as frequency multiplied by nutrient composition of specified portion size where
frequencies were measured in 9 categories from never/almost never to >6 servings/day
for each food item. Nutrient intake scores were computed using ad hoc computer software
specifically developed for this aim. A trained dietician updated the nutrient data bank
using the latest available information included in food composition tables for Spain [47,48].
A substudy in our cohort showed good reproducibility for assessing magnesium intake;
the Pearson correlation coefficients were 0.69 (<1 y between responses) and 0.65 (≥1 y
between responses) [46]. Adherence to the Mediterranean food pattern was assessed using
the 9-point score proposed by Trichopoulou et al. [49]. One point was assigned to per-
sons whose consumption was higher or equal to the sex-specific median of components
with most likely beneficial effects (vegetables, fruits/nuts, legumes, fish/seafood, cereals,
and monounsaturated/saturated fatty acid [MUFA/SFA] ratio), otherwise no point was
assigned; no point was assigned to persons with consumption higher or equal to the
sex-specific median of components proven not to be beneficial (meat and dairy products),
otherwise one point was assigned. For ethanol, one point was assigned to men consuming
10–50 g/day and to women consuming 5–25 g/day, otherwise no point was assigned.
2.4. Ascertainment of Incident Hypertension
The main outcome was defined by a medical diagnosis or self-report of hypertension
in any follow-up questionnaire, which has been formerly repeatedly validated [50–52].
In one of the validation substudies nested in the SUN cohort a subsample of the SUN
cohort participants who indicated a medical diagnosis of hypertension, were on antihy-
pertensive medication, or both in any of the follow-up questionnaires, two physicians
(blinded to the information reported by participants) did direct measurements of blood
pressure in the homes of participants who confirmed self-reported hypertension or self-
reported hypertension-free status in a subsample of the cohort. Considering blood pressure
>140/90 mmHg as confirmed by the 2018 European guidelines [53], 82.3% (95% confidence
interval (CI) 72.8, 92.8%) of self-reported hypertension in the questionnaires was confirmed.
Among those who did not report a diagnosis of hypertension in the questionnaires, 85.4%
(95% CI 72.4, 89.1%) were confirmed as non-hypertensives [50].
For the present study, participants with self-reported hypertension but missing in-
formation on the date of diagnosis, the mid-point between the date of completion of the
follow-up questionnaire with the self-reported medical diagnosis of hypertension and the
previous follow-up questionnaire were used to impute the date of diagnosis.
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2.5. Other Covariates
We considered the following additional covariates in the statistical models: socio-
demographic characteristics (age as a continuous variable and in 10 categories, sex, marital
status), anthropometric parameters (body weight, height, body mass index (BMI)), lifestyle
risk factors (physical activity, smoking habit in three categories, alcohol use, hours/day
spent watching television, following special diets, total energy intake, snacking between
meals, sugar-sweetened beverage consumption, years of university education), and other
confounding risk factors (borderline hypertension at baseline, family history of hyperten-
sion, sodium intake, potassium intake, calcium intake, fiber intake, analgesic consumption,
diuretic use). We assessed physical activity with a questionnaire formerly validated with
objective measurements using a triaxial accelerometer (RT3 Triaxial Research Tracker)
as reference (Spearman correlation coefficient of 0.51; p < 0.001) [54]. The magnitude of
physical activity was expressed in metabolic equivalent tasks (METs-h/week) according to
the calculation of the time spent at each activity in hours/week multiplied by its typical
energy expenditure [55]. Weight and BMI reported by each participant were previously
validated in a subsample of the SUN cohort [56].
2.6. Statistical Analysis
For the description of the baseline characteristics of the sample, we computed means
and SDs for continuous variables and proportions for categorical variables across categories
of daily dietary magnesium intake (<200 mg, 200–500 mg, >500 mg). We chose to use these
exact boundaries instead of quantiles because the groups thus built were more meaningful
per se and could be more easily used for future comparisons with similar studies. This is in
line with current recommendations given in epidemiology about procedures to categorize
continuous variables [57]. After a forward stepwise selection algorithm we used nested
regression models to evaluate the contribution of the main sources of dietary magnesium
intake to total dietary magnesium intake (Table 1).
Table 1. Main sources of variability (cumulative R2) and main sources (%) of dietary magnesium
intake among participants in the SUN (“Seguimiento Universidad de Navarra”) cohort, 1999–2016.






Fish and seafood 7.3 0.85
Vegetables: carrot, Swiss chard, cabbage, lettuce, tomatoes, green beans, eggplant, peppers, asparagus, other
fresh vegetables. Fruits: Citrus, banana, apple, pear, strawberry, peach, cherry, fig, melon, watermelon, grapes,
kiwi, mango, canned fruit. Dairy: milk (whole, low-fat, condensed, milkshake, cream), yogurt (whole, low-fat),
cheese (soft, hard, fresh, old, processed, curd), flan, ice cream. Nuts: almonds, peanuts, hazelnuts, pistachios,
pine nuts, walnuts. Legumes: lentils, chickpeas, beans, peas. Fish and Seafood: fish (white, blue, processed),
Seafood (oysters, prawns, octopus).
We calculated the follow-up time for each participant from the date of returning
the baseline questionnaire to the date of the diagnosis of incident hypertension or to the
date of returning the last follow-up questionnaire. We computed incident hypertension
rates across baseline categories of daily dietary magnesium intake, and calculated HRs
and 95% CI by means of Cox proportional hazards models using the lowest category of
magnesium intake as the reference. To test the proportional-hazards assumption we used
the test based on Schoenfeld residuals after fitting the model. Age was the underlying
time variable, and we performed various adjustments as follows: First, hazard ratios (HRs)
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were adjusted for age (10 categories used as stratification variables in the Cox model,
in addition to using age as the time variable) and sex; second, HRs were additionally
adjusted for BMI (in 5 categories), total energy intake (continuous), following special diets
at baseline, physical activity (METs-h/week), alcohol (g/d, continuous), and smoking
(3 categories); third, HRs were additionally adjusted for marital status (2 categories),
body weight changes, years of university education, borderline hypertension at baseline,
family history of hypertension, and year of entrance to the cohort; fourth, HRs were
additionally adjusted for sodium intake, potassium intake, calcium intake, fiber intake,
hours per day spent watching television (continuous), analgesic consumption, diuretic
use, and sugar-sweetened beverage consumption. We used dietary magnesium intake
as a continuous variable to calculate the significance of the linear trend tests. We used
multivariable-adjusted HR estimates to calculate dose–response associations between total
dietary magnesium intake and incident hypertension. We performed various sensitivity
analyses estimating the fully adjusted HRs for total dietary magnesium and incident
hypertension after changing several assumptions: (1) including only men or only women,
(2) adopting allowed limits for total energy intake from percentile 1 to 99, (3) censoring
the follow-up time of participants at 6 or 8 years, (4) excluding participants with early
incident hypertension (during the first 2 years), (5) adjusting for the Mediterranean diet
(MeDiet) score [49], (6) adjusting for dietary fiber intake, and (7) adjusting for diuretic use.
We also estimated the Pearson’s correlation coefficient between dietary magnesium intake
and both adherence to the traditional Mediterranean diet and dietary fiber intake. We
performed these analyses with Stata software package version 12 (Stata Corp). All p values
were 2-tailed and significance was set at p < 0.05. Values in the text are means ± SDs unless
otherwise indicated.
3. Results
3.1. Characteristics of Participants
Among 135,361 person—years of follow-up (mean follow-up: 9.6 years; range:
0.05–17.1 years) during the 1999–2016 period we observed 1406 cases of incident hyper-
tension in the SUN cohort. Table 2 displays the baseline characteristics of participants,
comprising anthropometric, demographic, and lifestyle features as well as food consump-
tion and nutrient intake, according to magnesium intake per day in three categories.
Participants with magnesium intake < 200 mg/d vs. those with >500 mg/d intake were
more likely to be men, single women, married men, current smokers, those with a former
history of depression or hypercholesterolemia, those with lower levels of leisure-time
physical activity, and those with a lower frequency of between-meal snacking. They were
also more likely to have lower scores of adherence to the MeDiet, less consumption of
vegetables, fruit, legumes, cereals, whole cereals, nuts, olive oil, eggs, fish, whole and
low-fat dairy, meat, coffee, total energy intake, and alcohol. They were more likely to
have higher intakes of total fat and mono and saturated fatty acids, and lower intakes
of vitamins C and D, iron from heme sources, folate, sodium, potassium, calcium, and
dietary fiber.
Table 2. Baseline characteristics of participants according to three categories of magnesium intake
among participants in the SUN (“Seguimiento Universidad de Navarra”) cohort, 1999–2016 a.
Magnesium Intake (mg/d)
<200 200–500 >500
Mg intake (mg/d) 155.1 ± 42.5 370.8 ± 72.8 588.7 ± 85.6
N 267 10782 3008
Women, % 63.7 66.6 68.7
Age, y 37.0 (11.3) 34.8 (10.5) 36.7 (11.2)




Married women, % 44.6 45.8 47.3
Married men, % 55.4 54.2 52.7
University education, y 5.1 5.0 5.0
BMI, kg/m2 23.5 (3.4) 23.0 (3.2) 22.9 (3.1)
Smoking
Current, % 33.3 27.3 21.7
Former smoker, % 18.7 21.5 23.5
Alcohol (g/d) 3.32 (5.21) 5.8 (8.48) 6.38 (9.75)
Leisure-time physical activity, METs-h/week 19.8 (21.4) 25.4 (21.7) 32.2 (28.6)
Television watching, h/d 1.6 (1.1) 1.6 (1.2) 1.6 (1.2)
History of depression at baseline, % 16.1 10.5 11.5
Hypercholesterolemia at baseline, % 16.9 13.0 14.1
Total energy intake, kcal/d 1110 (290) 2216 (518) 2947 (450)
Adoption of special diets, % 8.3 6.8 8.1
Between-meal snacking, % 28.2 34.5 64.7
Dietary consumption
Mediterranean diet score b 2.49 ± 1.1 3.74 ± 1.7 5.22 ± 1.6
Vegetables (g/d) 146 (137) 452 (229) 820 (465)
Fruit (g/d) 88 (109) 282 (203) 573 (420)
Legumes (g/d) 8.5 (10.2) 21 (13) 31 (28)
Cereals (g/d) 33 (38) 96 (66) 127 (80)
Whole bread (g/d) 1.2 (4.7) 1.2 (4.7) 29 (49)
Nuts (g/d) 1.6 (2.9) 5.4 (7.6) 14 (19)
Olive oil (g/d) 8.8 (12.3) 15 (13) 18 (14)
Eggs (g/d) 14 (15) 23 (15) 25 (16)
Fish and other seafood (g/d) 49 (42) 88 (50) 129 (77)
Whole dairy products (g/d) 106 (139) 197 (190) 224 (232)
Low-fat dairy products (g/d) 82 (121) 203 (218) 324 (315)
Meat (g/d) 100 (69) 173 (75) 194 (89)
Coffee (cups/d) 3.3 (2.6) 3.8 (2.4) 3.9 (2.5)
Sugar-sweetened beverages (servings/d) c 0.20 (0.5) 0.21 (0.4) 0.19 (0.4)
Dietary intake
Carbohydrates (% of energy) 39 (13) 43 (7.0) 46 (7.2)
Protein (% of energy) 18 (7.4) 18 (3.2) 18 (3.1)
Total fat (% of energy) 41 (10) 37 (6.3) 34 (6.3)
MUFAs (% of energy) 18 (6.4) 16 (3.6) 15 (3.4)
SFAs (% of energy) 15 (5.4) 13 (3) 11 (3.1)
PUFAs (% of energy) 5.5 (2.5) 5.2 (1.5) 5.0 (1.5)




Vitamin C (mg/d) 85 (72) 241 (113) 435 (193)
Vitamin D (mcg/d) 1.9 (1.7) 3.4 (2.1) 4.9 (3.2)
Iron from heme sources (mg/d) 6.7 (2.3) 15 (3.3) 23 (4.4)
Folate (mcg/d) 136 (71) 356 (111) 615 (197)
Na intake (mg/d) 2129 ± 1459 3785 ± 2112 4666 ± 2828
K intake (g/d) 1720 ± 612 4245 ± 962 6823 ± 1442
Ca intake (g/d) 502 ± 245 1129 ± 368 1651 ± 505
Dietary fiber (g/1000 kcal/d) 8.3 (4.8) 24 (7.4) 43 (13)
BMI: body mass index; MET: metabolic equivalent task; MUFA: monounsaturated fatty acid; SFA: saturated fatty
acid; PUFA: polyunsaturated fatty acid. a Values are mean (SD) unless otherwise stated. b The Mediterranean score
was calculated as proposed by Trichopoulou et al. [49]. c One serving of sugar-sweetened beverages = 200 mL.
3.2. Magnesium Intake, Incident Hypertension, and Obesity
As shown in Table 3, Table S1 (Supplementary Materials), and Figure 1, a significant
inverse association in the Cox models was observed for progressively higher magnesium
intake up to 500 mg/d after adjustments for sex and age, which remained significant after
multivariate adjustments (Models 2, 3, and 4) vs. an intake < 200 mg/d (reference). This
association was significant only for Model 3 for magnesium intakes > 500 mg/d (Table 3).
Considering diverse categories of BMI and of magnesium intake, the risk of developing
hypertension was still higher for participants with a magnesium intake < 200 mg/d and
BMI 23–27 kg/m2 and even greater for those with a BMI > 27 kg/m2 vs. participants with
a BMI < 23 kg/m2 (Figure S2, Supplementary Materials).
Table 3. Association between magnesium intake and incident hypertension among participants in the SUN (“Seguimiento
Universidad de Navarra”) cohort, 1999–2016 a.
Dietary Magnesium Categories of Daily Magnesium Intake (mg/day)
<200 200–300 300–400 400–500 >500 p-Trend
n 267 2051 4659 4072 3008
Incident hypertension (n) 43 212 459 354 338
Person—years 2698 19541 45294 39469 28359
Median (g/d) 168.9 267.4 353.0 444.5 536.5
Crude incident hypertension rate
(×10−3) 1.59 1.08 1.10 0.90 1.12
Age- and sex-adjusted HR Model 1 1 (ref.) 0.77 (0.56, 1.07) 0.73 (0.53, 0.99) 0.64 (0.46, 0.87) 0.78 (0.57, 1.07) 0.455
Multivariate-adjusted HR b Model 2 1 (ref.) 0.69 (0.49, 0.97) 0.66 (0.47, 0.94) 0.57 (0.39, 0.83) 0.69 (0.45, 1.04) 0.618
Multivariate-adjusted HR c Model 3 1 (ref.) 0.66 (0.47, 0.93) 0.64 (0.45, 0.90) 0.54 (0.37, 0.80) 0.66 (0.43, 0.99) 0.589
Multivariate-adjusted HR d Model 4 1 (ref.) 0.67 (0.47, 0.96) 0.65 (0.45, 0.95) 0.55 (0.36, 0.84) 0.66 (0.39, 1.10) 0.470
SUN, Seguimiento Universidad de Navarra. a Values are HR estimated with the Cox regression and 95% confidence intervals (CI). b Model
2: HR adjusted for age (10 categories), sex, body mass index (in five categories), total energy intake, following special diets at baseline,
physical activity (METs-h/week), alcohol (g/d), and smoking (three categories). c Model 3: HR adjusted for factors in Model 2 plus marital
status, body weight changes, years of university education, borderline hypertension at baseline, family history of hypertension, and year of
entrance to the cohort. d Model 4: HR adjusted for factors in Model 3 plus sodium intake, potassium intake, calcium intake, hours per day
spent watching television, analgesic consumption, and sugar-sweetened beverage consumption.
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Figure 1. Multivariable-adjusted hazard rati s for incident hypertension by categories of magnesium
intake (from <200 mg/d to >550 mg/d). The odel was adjusted for age, sex, BMI, total energy intake,
following special diets at baseline, physical activity, alcohol consumption, smoking, marital status,
body weight changes, years of university education, borderline hypertension at baseline, family
history of hypertension, year of entrance to th coh rt, sodium intake, potassium intake, calcium
intak , hours per day pent watching television, analgesic consumption, and sugar-sweetened
beverage consumption.
Taking into consideration participants with a magnesium intake less or greater than
200 mg/d and BMI less or greater than 25 kg/m2, the multivariate-adjusted risk of incident
hypertension was double for the latter with a low magnesium intake (Figure 2). Lean
participants (BMI < 25 kg/m2) with low magnesium intake (<200 mg/d) had a similar
risk as those who were overweight or obese with high magnesium intake (>200 mg/d)
(Figure 2). When we assessed the potential modifying effect of magnesium by BMI, we did
not find any statistically significant interaction (p = 0.12) with a four-degree of freedom
likelihood ratio test using magnesium in three categories (<200, 200–500, >500 mg/d) and
BMI in three categories (<23, 23–27, >27 kg/m2).
3.3. Magnesium Intake, Incident Hypertension, and Mediterranean Diet
We found a positive association of magnesium intake with the MeDiet adherence score
(r = 0.46; p < 0.0001). However, low magnesium intake was similarly associated with ~50%
relative increase in the risk of incident hypertension across categories of MeDiet adherence.
Within strata of low (<4) and high (≥4) scores of adherence to the MeDiet, the HRs for the
association between low magnesium and incident hypertension were similar, with values
of HR = 1.45 and HR = 1.38, respectively (Figure 3).
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Figure 2. Multivariate-adjusted HR of incident hypertension according to cross-classification by BMI
(lower and higher than 25 kg/m2) and magnesium intake (lower and higher than 200 mg/d) in
participants from the SUN Project. The model was adjusted for age, sex, BMI, total energy intake,
following special diets at baseline, physical activity, alcohol consumption, smoking, marital status,
body weight changes, years of university education, borderline hypertension at baseline, family
history of hypertension, year of entrance to the cohort, sodium intake, potassium intake, calcium
intake, hours per day spent watching television, analgesic consumption, and sugar-sweetened
beverage consumption.
Nutrients 2021, 13, x FOR PEER REVIEW 9 of 17 
 
 
history of hypertension, year of entrance to the cohort, sodium intake, potassium intake, calcium 
intake, hours per day spent watching television, analgesic consumption, and sugar-sweetened 
beverage consumption. 
3.3. Magnesium Intake, Incident Hypertensio , and Mediterranean Diet 
We found a positive association of magnesi m intake with the MeDiet adherence 
sc re (r = 0.46; p < 0.0001). How ver, low magnesium intake was similarly associa ed with 
~50% r lative incr ase in the risk of inci ent hype tension across categorie  of MeDiet
adherence. Within trata of l w (<4) and high (≥4) sc res of adh rence to the MeDiet, the 
HRs for the association b tween low magnesium and incident hypertension were similar, 
with v lues of HR = 1.45 and HR = 1.38, respectively (Figure 3). 
 
Figure 3. Multivariable-adjusted hazard ratios for incident hypertension. Joint exposure to Medi-
terranean diet score (lower and higher than four points) and magnesium intake (lower and higher 
than 200 mg/d). The model was adjusted for age, sex, BMI, total energy intake, following special 
diets at baseline, physical activity, alcohol consumption, smoking, marital status, body weight 
changes, years of university education, borderline hypertension at baseline, family history of hy-
pertension, year of entrance to the cohort, sodium intake, potassium intake, calcium intake, hours 
per day spent watching television, analgesic consumption, and sugar-sweetened beverage con-
sumption. 
3.4. Sensitivity Analyses 
We performed several sensitivity analyses for the significant multivariate-adjusted 
inverse association of dietary magnesium intake and incident hypertension (Table 4). 
This association remained significant in the different scenarios that we considered: after 
restricting the analyses only to women, censoring the follow-up time of participants at 
six or eight years, excluding participants with early incident hypertension (first two 
years), and after additional adjustment for the score of adherence to the MeDiet, dietary 
fiber intake, and diuretic use. Supplements of magnesium were used in only 8.5% of 
participants, with a very low mean dose in those taking them (40.8  50.7 mg/d). When 
we excluded participants who consumed magnesium supplements the results were not 
modified. 
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3.4. Sensitivity Analyses
We performed several sensitivity analyses for the significant multivariate-adjusted
inverse association of dietary magnesium intake and incident hypertension (Table 4).
This association remained significant in the different scenarios that we considered: after
restricting the analyses only to women, censoring the follow-up time of participants at six
or eight years, excluding participants with early incident hypertension (first two years),
and after additional adjustment for the score of adherence to the MeDiet, dietary fiber
intake, and diuretic use. Supplements of magnesium were used in only 8.5% of participants,
with a very low mean dose in those taking them (40.8 ± 50.7 mg/d). When we excluded
participants who consumed magnesium supplements the results were not modified.
Table 4. Sensitivity analyses: multivariable-adjusted hazard ratios of incident hypertension associated with low dietary
magnesium intake (<200 mg/d) among participants in the SUN Project, 1999–2016) a.
n Incident Hypertensionn HR (95% CI)
b
Main analysis 14,057 1406 1.51 (1.08, 2.11)
Including only women 9416 676 1.77 (1.10, 2.87)
Changing allowable energy limits (percentiles 1–99) c 14,944 1473 1.20 (0.70, 2.05)
Censoring follow-up at 8 y 9416 446 2.33 (1.25, 4.36)
Censoring follow-up at 6 y 9416 365 2.42 (1.12, 5.23)
Excluding early incident hypertension (first 2 y) 13,766 1210 1.54 (1.07, 2.21)
Adjusting for the Mediterranean diet score d 14,057 1406 1.48 (1.06, 2.06)
Adjusting for fiber intake 14,057 1406 1.48 (1.06, 2.06)
Adjusting for fiber intake below the median 14,057 1406 1.76 (1.01, 3.09)
Adjusting for use of diuretics 14,057 1406 1.48 (1.06, 2.07)
SUN, Seguimiento Universidad de Navarra. a Values are HR estimated with Cox regression and 95% CI. If the CI includes 1.00, the results
are not significant; p > 0.05 (two-tailed). b HR adjusted for age (10 categories), sex, BMI (in five categories), total energy intake, year
of entering the cohort (four categories), years of university education, smoking (three categories), borderline hypertension at baseline,
family history of hypertension, marital status, alcohol (g/d), physical activity (METs-h/week), body weight changes, hours per day spent
watching television, following special diets at baseline, snacking between meals, sodium intake, potassium intake, calcium intake, analgesic
consumption, and sugar-sweetened beverage consumption. c The criteria for exclusion here were only based on energy intake, but not on
the number of blank items. This is the reason why the number of participants was higher in this ancillary analysis. d The Mediterranean
score was calculated as proposed by Trichopoulou et al. [49].
4. Discussion
The present analyses on data from the SUN Project, a prospective, well-characterized,
and large cohort of Spanish university graduates, indicated that dietary magnesium intake
was inversely and significantly associated with the incidence of hypertension after a long-
term follow-up, independently of a number of potential confounders considered in the
fully adjusted statistical models. The risk of incident hypertension in this population
associated with low magnesium intake (<200 mg/d) was independent of adherence to the
MeDiet. Participants who were overweight and obese with magnesium intakes below 200
mg/d had a further significantly excess risk compared to lean and overweight or obese
participants with higher magnesium intake.
Previous studies assessing the relationship of dietary and supplemental magnesium
with the incidence of hypertension and diverse meta-analyses on cohort studies and RCTs
have reported protective effects [35–37,39]. A recent study examining meta-analyses on
the effects of electrolytes on hypertension showed that magnesium intake had the greatest
benefit, followed by potassium intake and by salt reduction [58]. As in our study, previous
studies evaluating the relationship of dietary magnesium and incident hypertension used as
reference a magnesium intake < 200 mg/day [27–29,35]. This consistent decision appears to
be based on a sound biological plausibility for assuming a deleterious effect of magnesium
intakes below 200 mg/d. Thus, previous evidence is in agreement with our results of an
inverse relationship of low magnesium intake and incident hypertension, for the first time
in a Mediterranean population.
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Several mechanisms can explain the protective effects of a diet rich in magnesium
against hypertension, including its calcium antagonist actions and its effects on endothelial
function, vascular tone, reactivity, and vascular cell growth [6–8,10,11,13,14,59]. Through
these actions magnesium has modulatory effects on blood pressure. Indeed, modifications
in magnesium status lead to alterations in vascular tone and, consequently, to fluctua-
tions in arterial blood pressure and reactivity, especially because of its calcium-antagonist
properties [7,8]. Magnesium deficiency stimulates angiotensin II-mediated aldosterone
production and the synthesis of thromboxane and prostaglandins with vasoconstrictor
effects [9]. Besides the direct actions of magnesium on vascular smooth muscle cells,
it also has modulatory actions on endothelial function, which in turn contributes to its
vasodilatory effects. In normal conditions, endothelium plays a key role in the regula-
tion of the vasomotor tone by synthesizing vasodilatory prostacyclins and nitric oxide.
Magnesium has been shown to improve endothelial function in humans [10,11] and to
be associated with circulating markers of systemic inflammation and endothelial dys-
function in women [12]. Magnesium was shown to participate in vascular structure and
remodeling [13], whereas magnesium-signaling increased endothelial survival, adhesion,
migration, and growth [59].
We observed that the deleterious effects of a magnesium intake below 200 mg/d
on incident hypertension were dramatically worse in overweight and obese participants.
Obesity is a well-recognized risk factor for hypertension [1,3,4]. In particular, excessive
visceral fat distribution is associated with hormonal, inflammatory, and endothelial al-
terations, which increase hypertension risk and cardiovascular morbidity and mortality.
It is widely accepted that BMIs corresponding to the WHO classification of overweight
(>25 kg/m2) or obese (>30 kg/m2) are related to an increased risk of incident hypertension.
However, these categories include several levels of BMI and do not allow us to perceive
in detail the linear association of overweight/obesity and incident hypertension. There is
evidence in several studies and populations of a significant and linear increase in blood
pressure and incident hypertension for BMI values greater than 22 kg/m2 [60–62]. Even at
values considered “normal” by the WHO classification (20–25 kg/m2), those persons with
a BMI greater than 22–23 kg/m2 have a significantly higher risk of incident hypertension
compared to those with lower BMI values. In the present study, we observed that in
persons with a BMI 23–27 kg/m2 and more so in those with a BMI > 27 kg/m2, the risk
of hypertension was multiplied if they had a magnesium-deficient diet, which might add
another pathophysiological key mediator linked to a magnesium deficit.
Interestingly, participants with a BMI < 25 kg/m2 and magnesium intake < 200 mg/d
had a similar risk of developing hypertension as those with a BMI > 25 kg/m2 with an
adequate magnesium intake (Figure 2). This could correspond to metabolically obese
normal-weight (MONW) participants, described since 1981 [63,64]. These patients with a
BMI < 25 kg/m2 have metabolic abnormalities more commonly observed in obese patients,
such as abdominal fat distribution, insulin resistance, hypertriglyceridemia, and high
blood pressure. Although the definition of MONW patients has not been univocal, some
metabolic (i.e., triglyceride index) [65] and genetic markers [66] have been described in
order to identify these high-risk patients. This condition has been associated with low
concentrations of serum magnesium [67], and improvements in blood pressure, fasting
glucose, and triglyceride concentrations after oral magnesium administration have been
reported in MONW persons [68].
Furthermore, participants with a BMI > 25 kg/m2 and adequate magnesium intake
had lower risk of incident hypertension vs. overweight or obese participants with low
magnesium intake, reinforcing the protective effect of dietary magnesium intake against
hypertension even in obese persons. This may suggest the protective effect of dietary
magnesium intake against obesity-associated hypertension, and that insufficient dietary
magnesium intake is associated with increased risk of hypertension in all, regardless
of weight.
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The positive relationship of dietary magnesium intake with the MeDiet adherence
score in our cohort (r = 0.46; p < 0.0001) may lead one to think that the overall dietary quality
may account for the protection apparently afforded by magnesium in our results. However,
we observed that the inverse association of dietary magnesium with incident hypertension
was similar regardless of adherence to the MeDiet. Most, but not all, MeDiet components
contain magnesium; our results might indicate that those components rich in magnesium
content (i.e., vegetables, nuts, whole cereals, legumes) were particularly protective even
when other points of the MeDiet adherence score were not met. Participants with low
conformity to this dietary pattern with an adequate magnesium intake were protected, as
were obese participants with an adequate magnesium intake. Of note, nearly all magnesium
intake in our cohort was from dietary sources, and the use of magnesium supplements was
marginal and at low doses.
We observed a strong correlation between dietary magnesium and fiber intakes
(r = 0.87; p < 0.0001). This has been reported in previous studies [69–72] and is related
to the fact that both nutrients are contained in the same type of foods. Furthermore, in
some studies the association of dietary magnesium intake with metabolic outcomes was
attenuated when the results were adjusted for dietary fiber [70–72].
Regarding the association of dietary fiber intake and incident hypertension, the results
are not yet completely conclusive [73]. Interestingly, the association that we observed
between a low magnesium intake and incident hypertension remained significant after
adjusting for dietary fiber intake in the sensitivity analyses (Table 4).
It should be also considered that the absorption, hence, bioavailability of magnesium
is reduced with high amounts of fiber intake [74], such as what we observed in the category
of higher magnesium intake (>500 mg/d), where the significance of the association with
incident hypertension was marginal.
Currently, nutrition research underscores the relevance of studying food and nutrient
combinations, as opposed to the reductionist approach based on single nutrients or foods
widely used in the past. Dietary patterns reported to significantly reduce blood pressure in
hypertensive and pre-hypertensive patients include Dietary Approaches to Stop Hyper-
tension (DASH) and the MeDiet [75]. Interestingly, DASH, ranked as the most effective
dietary model in reducing blood pressure [75], emphasizes the high content of minerals,
including magnesium. Nevertheless, it is unlikely that magnesium alone is responsible
for the hypertension preventive effects of these dietary patterns, but it is confidently an
important independent determinant, remaining significant after multivariate adjustments
and regardless high or low conformity with the MeDiet. It should be remembered that
foods rich in magnesium are also rich in other components with recognized health benefits.
The independent effects of magnesium and the detrimental consequences of a magnesium-
poor diet even in lean persons may identify a missing piece of the puzzle in order to
help explain mechanistically why a diet rich in vegetables, fruit, nuts, whole cereals, and
legumes has anti-hypertensive and cardiovascular benefits. Thus, magnesium seems to
have a strong protective effect against hypertension in a world where the Western diet, rich
in ultra-processed foods and poor in magnesium, is frequently followed [19–22], but we
admit that magnesium likely acts in conjunction and harmony with other nutrients present
in the same food sources as magnesium.
Among the strengths of the present study we include the large sample size, the
prospective design, the extensive follow-up, the high retention rate, and the possibility to
adjust for numerous confounding factors. Potential limitations include that, regardless of
the SUN cohort characteristic, the application of our results in other contexts must be based
on common biological mechanisms and not on simple statistical “representativeness.” Thus,
we used restriction to reduce potential confounding factors, such as socioeconomic status,
education, disease, and expected access to health care. Future studies are needed in order to
test our findings in other populations. Another limitation could be the use of self-reported
information; however, self-reported parameters such as hypertension, weight and BMI
have been previously validated [50–52,56]. In the fully adjusted multivariate analyses,
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when dietary magnesium beyond 500 mg/day is not significantly associated with incident
hypertension it might be due to the lower number of participants in that group and the
consequent reduction in statistical power. Furthermore, although the size of the group may
be similar to the one that consumed 200–300 mg of magnesium per day and was significant,
the confounders added in the fully adjusted multivariate analysis increased the standard
error in the >500 mg/day group, perhaps because it was the extreme group, which had
more different values in the confounders. However, all point estimates suggest an inverse
association with the association being significant in one of the multivariate adjusted models
(Model 3). For some other confounding factors such as phytate, long-chain triglycerides,
proton pump inhibitors, and glomerular filtration rate, we did not have enough information
to include them in the analyses. The use of a validated FFQ in a prospective cohort does not
fully preclude the possibility of non-differential information bias, but we found sensible
correlation coefficients for the exposures. Because the potential measurement error in the
assessment of diet is expected to be non-differential, it would likely bias our results towards
the null value. FFQ remains a useful and inexpensive method to characterize dietary habits
of large samples followed over extended periods of time, aiming to assess associations with
incident clinical outcomes [76]. Another limitation is the possible change in customary diet,
and thus in magnesium status, during follow-up.
5. Future Lines of Research
Based on our present results in a Mediterranean cohort and those of previous studies
from other regions cited above, the populations that currently tend towards a diet poor in
magnesium can benefit from correcting this deficit through the introduction and sufficient
use of magnesium-rich foods in their usual diets.
Furthermore, the benefit is multiplied by the fact that these same foods contain other
substances that are beneficial to health.
It is clear that people with a higher cardiovascular risk, including those with a higher
risk for hypertension, would benefit the most. Nevertheless, more evidence is needed from
other populations, e.g., from Asia, South America, Africa, and other European countries,
which may help in further developing healthy dietary recommendations and interventions.
6. Conclusions
A dietary pattern with magnesium intake below 200 mg/d was strongly and inde-
pendently associated with a higher risk of developing hypertension in a relatively young
Mediterranean cohort. This association was worse for overweight and obese participants
and independent of the conformity with the Mediterranean dietary pattern. These re-
sults emphasize the importance of controlling overweight and to broadly encourage the
consumption of foods such as vegetables, nuts, whole cereals, and legumes, optimal di-
etary sources of magnesium, in order to prevent hypertension, the main risk factor for
cardiovascular and cerebrovascular events in all populations.
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